An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Phase 1 Unknown 18 enrolled First Affiliated Hospital of Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.

Timeline

Start: 2020-07-25
Primary completion: 2022-05-11
Completion: 2022-06-25

Publications

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells	Cell therapy	1 cells/kg	Other
Subject	Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells	Cell therapy	3 cells/kg	Other
Subject	Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells	Cell therapy	5 cells/kg	Other

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Summary

Timeline

Publications

Drugs

Indications